RNXT RenovoRx, Inc.
Price Chart
Executive Summary
RenovoRx announced the publication of a PK/PD sub-study from its Phase III TIGeR-PaC trial at ASCO 2026, showing that intra-arterial gemcitabine via RenovoCath reduces systemic drug exposure and increases metabolite levels correlated with CA 19-9 reduction. The company also reported $1.1M in RenovoCath sales for 2025 and $563K in Q1 2026, with full trial enrollment expected in June 2026 and final data in mid-late 2027. The sub-study is a modest positive signal for the TAMP platform but does not change the binary risk of the Phase III readout.
Key Financial Metrics
Actionable Insight
The sub-study is a modest positive for the TAMP platform's scientific credibility but does not derisk the binary Phase III outcome. Monitor for full enrollment announcement (June 2026) and final data (mid-late 2027). The stock's historical volatility and poor win rate suggest caution — avoid chasing the ASCO abstract pop.
Key Facts
- PK/PD sub-study of Phase III TIGeR-PaC trial published online for ASCO 2026 (May 29-June 2).
- IAG (intra-arterial gemcitabine via RenovoCath) showed reduced systemic gemcitabine levels and increased inactive metabolite, correlated with CA 19-9 reduction in 16 patients.
- RenovoCath sales: $1.1M in FY2025, $563K in Q1 2026.
- Full TIGeR-PaC enrollment expected June 2026; final data readout mid-late 2027.
- IAG has Orphan Drug Designation for pancreatic and bile duct cancer.
Financial Impact
Commercial revenue of $1.1M in 2025 and $563K in Q1 2026; no financial impact from sub-study itself.
Risk Factors
- Phase III TIGeR-PaC trial may fail to meet endpoints, rendering the sub-study moot.
- Low commercial revenue ($1.1M) and cash burn risk; company may need additional financing.
- Historical T+20 performance on RNXT is poor (11% win rate, avg -15.19% return).
Market Snapshot
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301084 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
May 26, 2026
18d ago
|
Press Release
| $0.9160 $0.9210 | ▲ +0.55% | ▼ −0.54% | $0.8440 (−7.86%) |
|
May 19, 2026
25d ago
|
Press Release
| $0.8060 $0.9052 | ▲ +12.31% | ▲ +10.06% | $0.8440 (+4.71%) |
|
May 15, 2026
28d ago
|
10-K/A
| $0.7830 $0.9160 | ▲ +16.99% | ▲ +15.37% | $0.8440 (+7.79%) |
|
May 14, 2026
29d ago
|
8-K
| $0.8200 $0.8820 | ▲ +7.56% | ▲ +6.60% | $0.8440 (+2.93%) |
|
Apr 29, 2026
6w ago
|
Press Release
| $0.8310 $0.9280 | ▲ +11.67% | ▲ +8.56% | $0.8440 (+1.56%) |
|
Apr 28, 2026
6w ago
|
EFFECT
| $0.8400 $0.9280 | ▲ +10.48% | ▲ +8.78% | $0.8440 (+0.48%) |
|
Apr 16, 2026
8w ago
|
S-3
| $1.00 $0.8570 | ▼ −14.30% | ▼ −14.85% | $0.8440 (−15.60%) |
|
Apr 14, 2026
8w ago
|
Press Release
| $1.03 $0.9490 | ▼ −7.86% | ▼ −9.26% | $0.8440 (−18.06%) |
|
Mar 30, 2026
10w ago
|
8-K
| $1.01 $0.9390 | ▼ −7.03% | ▼ −10.97% | $0.8440 (−16.44%) |
|
Mar 30, 2026
10w ago
|
Press Release
| $1.01 $0.9390 | ▼ −7.03% | ▼ −10.97% | $0.8440 (−16.44%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access